antibody

Bio & Pharma Samsung, Celltrion lead biosimilar market in Europe, US

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Celltrion to establish CDMO subsidiary

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Bio & Pharma Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

Bio & Pharma Lotte Biologics, NJ Bio to jointly develop ADC

South Korea's Lotte Biologics Co. announced on Monday that it has signed a strategic business agreement with NJ Bio, a US-based preclinical and clin...

Mergers & Acquisitions Orion to buy control of biotech startup LegoChem for $415 mn

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

Bio & Pharma Celltrion, Cyron to develop multi-specific antibody new drug

South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...

Bio & Pharma 'World-class bispecific antibody technology of ABL Bio'

MADRID - "The clinical Phase 1 results of the immune-oncology candidate ABL111, developed in collaboration with ABL Bio, have been selected as the b...

Bio & Pharma Lotte builds US antibody-drug conjugate plant with $82 mn

South Korea’s Lotte Biologics Co. is establishing an antibody-drug conjugate (ADC) factory in Syracuse, New York, with an investment of 110 bi...

Bio & Pharma HLB gets global rights to Chinese liver cancer drug

South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...

Bio & Pharma Hanmi Pharm to start global clinical trials for immune-oncology drug

South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology...

Bio & Pharma Celltrion, Genuv sign agreement for antibody joint R&D

South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...

Bio & Pharma Chong Kun Dang, Synaffix ink deal to introduce ADC technology

Chong Kun Dang Pharmaceutical Corp. said on Monday that it has signed a contract with Dutch biotechnology firm Synaffix B.V for the use of antibody-...

Bio & Pharma Bridge Biotherapeutics, Pinotbio develop lung cancer treatment

South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...

Bio & Pharma Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. ...

Bio & Pharma Celltrion develops oral antibody drug with US bio company

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

Bio & Pharma Celltrion's Remsima receives approval in 100 countries in 10 years

South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...

Bio & Pharma S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer

South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...

Bio & Pharma PCL’s diagnostic kit measures concentration of COVID-19 antibodies

PCL Inc., a South Korean in vitro diagnostics device maker, plans to bring two test kits – one that simultaneously detects COVID-19 and influenza infe...

Korean biotech startup signs license deal with US firm

South Korea's biotech startup Novelty Nobility Inc. has signed a global license agreement for its antibody treatment candidate with a US biopharmace...

Pharamaceuticals, biotech Celltrion to conduct tests on Omicron variant detected in Korea

Biopharmaceutical powerhouse Celltrion Inc. plans to use its treatments to test the Omicron variant detected in Korea, according to a high-level com...

Biotech LegoChem’s biotech platform drives 28% share price spike over last month

The rise of the platform economy is a global phenomenon. The spread of the coronavirus pandemic has accelerated the use of contactless technology an...

Medicine Celltrion, Mirae to take largest stake in UK biotech firm

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...

COVID-19 Celltrion says COVID-19 antibody kills virus within 5 days; shares surge

South Korea’s biopharmaceutical firm Celltrion Inc. can unveil an antibody treatment by around the end of the year that is able to kill the COVI...